Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1971 1
1972 1
1973 2
1976 2
1977 2
1978 1
1979 3
1980 1
1981 1
1982 1
1983 2
1984 4
1985 1
1986 15
1987 10
1988 16
1989 18
1990 13
1991 13
1992 10
1993 11
1994 15
1995 11
1996 12
1997 14
1998 9
1999 16
2000 11
2001 11
2002 14
2003 17
2004 15
2005 12
2006 20
2007 16
2008 19
2009 14
2010 15
2011 17
2012 16
2013 6
2014 15
2015 11
2016 14
2017 12
2018 15
2019 23
2020 31
2021 35
2022 43
2023 40
2024 14

Text availability

Article attribute

Article type

Publication date

Search Results

612 results

Results by year

Filters applied: . Clear all
Page 1
Pentosan polysulfate maculopathy.
Lindeke-Myers A, Hanif AM, Jain N. Lindeke-Myers A, et al. Surv Ophthalmol. 2022 Jan-Feb;67(1):83-96. doi: 10.1016/j.survophthal.2021.05.005. Epub 2021 May 14. Surv Ophthalmol. 2022. PMID: 34000253 Review.
Pentosan polysulfate sodium (PPS), a semisynthetic sulfated polysaccharide, is the only FDA-approved oral therapy for interstitial cystitis. ...
Pentosan polysulfate sodium (PPS), a semisynthetic sulfated polysaccharide, is the only FDA-approved oral therapy for intersti …
Pentosan polysulfate and a pigmentary maculopathy: causation versus correlation?
Proctor JG. Proctor JG. Can J Urol. 2023 Dec;30(6):11732-11739. Can J Urol. 2023. PMID: 38104330 Free article. Review.
INTRODUCTION: Interstitial cystitis (IC) is a chronic disease with urinary tract symptoms and pain. Pentosan polysulfate (PPS) is the only U.S. Food and Drug Administration approved oral medication for the treatment of IC pain and symptoms. ...
INTRODUCTION: Interstitial cystitis (IC) is a chronic disease with urinary tract symptoms and pain. Pentosan polysulfate (PPS) …
Pentosan Polysulfate Maculopathy.
Margines JB, Tripathy K, Hobbs SD. Margines JB, et al. 2024 Mar 1. In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2024 Jan–. 2024 Mar 1. In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2024 Jan–. PMID: 36944010 Free Books & Documents.
Pentosan polysulfate (PPS) is a semisynthetic pentasaccharide heparinoid with anticoagulant properties. ...
Pentosan polysulfate (PPS) is a semisynthetic pentasaccharide heparinoid with anticoagulant properties. ...
Pentosan Polysulfate Affords Pleotropic Protection to Multiple Cells and Tissues.
Smith MM, Melrose J. Smith MM, et al. Pharmaceuticals (Basel). 2023 Mar 13;16(3):437. doi: 10.3390/ph16030437. Pharmaceuticals (Basel). 2023. PMID: 36986536 Free PMC article. Review.
Pentosan polysulfate (PPS), a small semi-synthetic highly sulfated heparan sulfate (HS)-like molecule, shares many of the interactive properties of HS. ...
Pentosan polysulfate (PPS), a small semi-synthetic highly sulfated heparan sulfate (HS)-like molecule, shares many of the inte …
Pentosan Polysulfate, a Semisynthetic Heparinoid Disease-Modifying Osteoarthritic Drug with Roles in Intervertebral Disc Repair Biology Emulating the Stem Cell Instructive and Tissue Reparative Properties of Heparan Sulfate.
Smith MM, Hayes AJ, Melrose J. Smith MM, et al. Stem Cells Dev. 2022 Aug;31(15-16):406-430. doi: 10.1089/scd.2022.0007. Epub 2022 Mar 14. Stem Cells Dev. 2022. PMID: 35102748 Review.
This review highlights the attributes of pentosan polysulfate (PPS) in the promotion of intervertebral disc (IVD) repair processes. ...
This review highlights the attributes of pentosan polysulfate (PPS) in the promotion of intervertebral disc (IVD) repair proce …
Pentosan polysulfate maculopathy versus age-related macular degeneration: comparative assessment with multimodal imaging.
Christiansen JS, Barnes AC, Berry DE, Jain N. Christiansen JS, et al. Can J Ophthalmol. 2022 Feb;57(1):16-22. doi: 10.1016/j.jcjo.2021.02.007. Epub 2021 Mar 12. Can J Ophthalmol. 2022. PMID: 33722504
Pentosan polysulfate exposure characteristics were compared among groups. ...Eyes with pentosan polysulfate maculopathy did not have typical drusen in the macula. ...
Pentosan polysulfate exposure characteristics were compared among groups. ...Eyes with pentosan polysulfate macu …
Update on maculopathy secondary to pentosan polysulfate toxicity.
Abou-Jaoude M, Fraser C, Maldonado RS. Abou-Jaoude M, et al. Curr Opin Ophthalmol. 2021 May 1;32(3):233-239. doi: 10.1097/ICU.0000000000000754. Curr Opin Ophthalmol. 2021. PMID: 33710012 Review.
PURPOSE OF REVIEW: The aim of the present review is to provide a comprehensive summary of available knowledge regarding toxic maculopathy secondary to pentosan polysulfate sodium (PPS). RECENT FINDINGS: PPS toxicity was described in 2018, and additional studies char …
PURPOSE OF REVIEW: The aim of the present review is to provide a comprehensive summary of available knowledge regarding toxic maculopathy se …
Pentosan Polysulfate Maculopathy: What Urologists Should Know in 2020.
Paredes Mogica JA, De EJB. Paredes Mogica JA, et al. Urology. 2021 Jan;147:109-118. doi: 10.1016/j.urology.2020.08.072. Epub 2020 Oct 10. Urology. 2021. PMID: 33045286
Databases searched included PubMed, Ovid, Medline, EBSCO, and Google Scholar. A search was conducted for the terms "Pentosan Polysulfate Maculopathy," "Pentosan Polysulfate Retinopathy," and "Interstitial Cystitis Maculopathy." ...Most papers reported …
Databases searched included PubMed, Ovid, Medline, EBSCO, and Google Scholar. A search was conducted for the terms "Pentosan Polys …
Pentosan polysulfate for the treatment of hemorrhagic cystitis after allogeneic hematopoietic cell transplant.
Hatch RV, Freyer CW, Carulli A, Luger SM, Martin ME, McCurdy SR, Porter DL, Loren AW. Hatch RV, et al. J Oncol Pharm Pract. 2022 Oct;28(7):1609-1612. doi: 10.1177/10781552221105295. Epub 2022 May 31. J Oncol Pharm Pract. 2022. PMID: 35642262
The median time to symptom resolution from pentosan polysulfate initiation was 9 days (range: 7-10). CONCLUSION: Pentosan polysulfate was well-tolerated and seemed to assist with symptom resolution. Future studies are needed to confirm the impact of …
The median time to symptom resolution from pentosan polysulfate initiation was 9 days (range: 7-10). CONCLUSION: Pentosan …
612 results